To the Editor:
I can't thank you all enough for all of your support with the Raymond James Boca Grande Classic and taking time out of your busy schedules to join us for this special event May 2-5.
The tournament is truly a team effort and we could not have done it without each and every one of you. Thank you for supporting Cystic Fibrosis Foundation; I hope you feel proud of what you have accomplished.
We were successful in netting more than $97,000 with the event.
Also, I wanted to share some encouraging news in our work to develop new CF treatments: Vertex Pharmaceuticals announced that interim data from the Phase 2 combination study of VX-809 and Kalydeco showed significant improvements in lung function in people with cystic fibrosis who have two copies of the Delta F508 mutation.
The interim data are from the second part of the ongoing Phase 2 combination study. A significant number of patients with two copies of Delta F508 exhibited an improvement in lung function of 5 percent or greater after exposure to both drugs.
Vertex released the data to accelerate its plans for a pivotal study of the two drugs cf patients with two copies of Delta F508 pending the results of the complete study in mid-summer. The impact of the combination therapy on those with one copy of Delta F508 is not yet known.
These interim results further validate our approach to treating the underlying causes of CF.
I'm excited to share this news as we celebrate Cystic Fibrosis Awareness month. Here is the link to Vertex's press release: investors.vrtx.com/releasedetail.cfm?ReleaseID=670755
We are looking forward to seeing all of you next year! Please mark your calendars for May 1-3, 2013, at the legendary Gasparilla Inn & Club.
Thanks again!
Jennifer Buchanan
development director
Cystic Fibrosis Foundation South Florida
Fort Lauderdale
